Literature DB >> 16306385

The emerging role of the endocannabinoid system in endocrine regulation and energy balance.

Uberto Pagotto1, Giovanni Marsicano, Daniela Cota, Beat Lutz, Renato Pasquali.   

Abstract

During the last few years, the endocannabinoid system has emerged as a highly relevant topic in the scientific community. Many different regulatory actions have been attributed to endocannabinoids, and their involvement in several pathophysiological conditions is under intense scrutiny. Cannabinoid receptors, named CB1 receptor and CB2 receptor, first discovered as the molecular targets of the psychotropic component of the plant Cannabis sativa, participate in the physiological modulation of many central and peripheral functions. CB2 receptor is mainly expressed in immune cells, whereas CB1 receptor is the most abundant G protein-coupled receptor expressed in the brain. CB1 receptor is expressed in the hypothalamus and the pituitary gland, and its activation is known to modulate all the endocrine hypothalamic-peripheral endocrine axes. An increasing amount of data highlights the role of the system in the stress response by influencing the hypothalamic-pituitary-adrenal axis and in the control of reproduction by modifying gonadotropin release, fertility, and sexual behavior. The ability of the endocannabinoid system to control appetite, food intake, and energy balance has recently received great attention, particularly in the light of the different modes of action underlying these functions. The endocannabinoid system modulates rewarding properties of food by acting at specific mesolimbic areas in the brain. In the hypothalamus, CB1 receptor and endocannabinoids are integrated components of the networks controlling appetite and food intake. Interestingly, the endocannabinoid system was recently shown to control metabolic functions by acting on peripheral tissues, such as adipocytes, hepatocytes, the gastrointestinal tract, and, possibly, skeletal muscle. The relevance of the system is further strenghtened by the notion that drugs interfering with the activity of the endocannabinoid system are considered as promising candidates for the treatment of various diseases, including obesity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16306385     DOI: 10.1210/er.2005-0009

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  217 in total

Review 1.  The thrifty lipids: endocannabinoids and the neural control of energy conservation.

Authors:  Nicholas V DiPatrizio; Daniele Piomelli
Journal:  Trends Neurosci       Date:  2012-05-22       Impact factor: 13.837

2.  The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice.

Authors:  Garron T Dodd; Giacomo Mancini; Beat Lutz; Simon M Luckman
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

Review 3.  New insights on the role of the endocannabinoid system in the regulation of energy balance.

Authors:  B Gatta-Cherifi; D Cota
Journal:  Int J Obes (Lond)       Date:  2015-09-16       Impact factor: 5.095

Review 4.  Marijuana, phytocannabinoids, the endocannabinoid system, and male fertility.

Authors:  Stefan S du Plessis; Ashok Agarwal; Arun Syriac
Journal:  J Assist Reprod Genet       Date:  2015-08-16       Impact factor: 3.412

5.  Rimonabant.

Authors:  Sheridan Henness; Dean M Robinson; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2006       Impact factor: 9.546

6.  A novel GPR55-mediated satiety signal in the oval Bed Nucleus of the Stria Terminalis.

Authors:  E R Hawken; C P Normandeau; J Gardner Gregory; B Cécyre; J-F Bouchard; K Mackie; É C Dumont
Journal:  Neuropsychopharmacology       Date:  2019-01-07       Impact factor: 7.853

7.  The G1422A variant of the cannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men.

Authors:  Armand Peeters; Sigri Beckers; Ilse Mertens; Wim Van Hul; Luc Van Gaal
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

Review 8.  The endocannabinoid system in obesity and type 2 diabetes.

Authors:  V Di Marzo
Journal:  Diabetologia       Date:  2008-06-18       Impact factor: 10.122

9.  Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance.

Authors:  Joseph Tam; Resat Cinar; Jie Liu; Grzegorz Godlewski; Daniel Wesley; Tony Jourdan; Gergő Szanda; Bani Mukhopadhyay; Lee Chedester; Jeih-San Liow; Robert B Innis; Kejun Cheng; Kenner C Rice; Jeffrey R Deschamps; Robert J Chorvat; John F McElroy; George Kunos
Journal:  Cell Metab       Date:  2012-07-26       Impact factor: 27.287

10.  Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes.

Authors:  Dai Lu; Rachel Dopart; Debra A Kendall
Journal:  Cell Stress Chaperones       Date:  2016-01       Impact factor: 3.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.